Genetic diversity of Mycobacterium tuberculosis strains circulating in Botswana.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
02
2019
accepted:
17
04
2019
entrez:
8
5
2019
pubmed:
8
5
2019
medline:
15
1
2020
Statut:
epublish
Résumé
Molecular typing of Mycobacterium tuberculosis (M.tb) isolates can inform Tuberculosis (TB) control programs on the relative proportion of transmission driving the TB epidemic. There is limited data on the M. tb genotypes that are circulating in Botswana. The aim of this study was to generate baseline data on the genetic diversity of M.tb isolates circulating in the country. A total of 461 M.tb isolates received at the Botswana National Tuberculosis Reference Laboratory between March 2012 and October 2013 were included in this study. Drug susceptibility testing was conducted using the BD BACTEC MGIT 960 System. M.tb strains were genotyped using spoligotyping and spoligotype patterns were compared with existing patterns in the SITVIT Web database. A subset of drug resistant isolates which formed spoligo clusters (n = 65) was additionally genotyped with 12-loci MIRU. Factors associated with drug resistance and clustering were evaluated using logistic regression. Of the 461 isolates genotyped, 458 showed 108 distinct spoligotype patterns. The predominant M.tb lineages were Lineage 4 (81.9%), Lineage 2 (9%) and Lineage 1 (7.2%). The predominant spoligotype families within Lineage 4 were LAM (33%), S (14%), T (16%), X (16%). Three hundred and ninety-two (86%) isolates could be grouped into 44 clusters (2-46 isolates per cluster); giving a clustering rate of 76%. We identified 173 (37.8%) drug resistant isolates, 48 (10.5%) of these were multi-drug resistant. MIRU typing of the drug resistant isolates allowed grouping of 46 isolates into 14 clusters, giving a clustering rate of 49.2%. There was no association between age, sex, treatment category, region and clustering. This study highlights the complexity of the TB epidemic in Botswana with multiple strains contributing to disease and provides baseline data on the population structure of M.tb strains in Botswana.
Sections du résumé
BACKGROUND
Molecular typing of Mycobacterium tuberculosis (M.tb) isolates can inform Tuberculosis (TB) control programs on the relative proportion of transmission driving the TB epidemic. There is limited data on the M. tb genotypes that are circulating in Botswana. The aim of this study was to generate baseline data on the genetic diversity of M.tb isolates circulating in the country.
METHODS
A total of 461 M.tb isolates received at the Botswana National Tuberculosis Reference Laboratory between March 2012 and October 2013 were included in this study. Drug susceptibility testing was conducted using the BD BACTEC MGIT 960 System. M.tb strains were genotyped using spoligotyping and spoligotype patterns were compared with existing patterns in the SITVIT Web database. A subset of drug resistant isolates which formed spoligo clusters (n = 65) was additionally genotyped with 12-loci MIRU. Factors associated with drug resistance and clustering were evaluated using logistic regression.
RESULTS
Of the 461 isolates genotyped, 458 showed 108 distinct spoligotype patterns. The predominant M.tb lineages were Lineage 4 (81.9%), Lineage 2 (9%) and Lineage 1 (7.2%). The predominant spoligotype families within Lineage 4 were LAM (33%), S (14%), T (16%), X (16%). Three hundred and ninety-two (86%) isolates could be grouped into 44 clusters (2-46 isolates per cluster); giving a clustering rate of 76%. We identified 173 (37.8%) drug resistant isolates, 48 (10.5%) of these were multi-drug resistant. MIRU typing of the drug resistant isolates allowed grouping of 46 isolates into 14 clusters, giving a clustering rate of 49.2%. There was no association between age, sex, treatment category, region and clustering.
CONCLUSIONS
This study highlights the complexity of the TB epidemic in Botswana with multiple strains contributing to disease and provides baseline data on the population structure of M.tb strains in Botswana.
Identifiants
pubmed: 31063472
doi: 10.1371/journal.pone.0216306
pii: PONE-D-19-03820
pmc: PMC6504092
doi:
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0216306Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 107752/Z/15/Z
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Med. 2006 Oct;3(10):e384
pubmed: 17020405
J Clin Microbiol. 1993 Feb;31(2):406-9
pubmed: 8381814
PLoS One. 2012;7(10):e47113
pubmed: 23077552
PLoS One. 2018 Jun 4;13(6):e0197737
pubmed: 29864118
BMC Infect Dis. 2017 Dec 12;17(1):764
pubmed: 29233106
PLoS One. 2018 Aug 1;13(8):e0200632
pubmed: 30067763
Int J Tuberc Lung Dis. 2014 Sep;18(9):1026-33
pubmed: 25189548
J Clin Microbiol. 2006 Dec;44(12):4498-510
pubmed: 17005759
J Clin Microbiol. 2001 Oct;39(10):3563-71
pubmed: 11574573
Infect Genet Evol. 2012 Jun;12(4):755-66
pubmed: 22365971
EBioMedicine. 2018 Nov;37:410-416
pubmed: 30341041
J Infect Dis. 2018 Nov 5;218(12):1964-1973
pubmed: 29961879
PLoS Negl Trop Dis. 2016 Mar 10;10(3):e0004408
pubmed: 26964059
N Engl J Med. 2003 Sep 18;349(12):1149-56
pubmed: 13679530
J Clin Microbiol. 2008 Aug;46(8):2692-9
pubmed: 18550737
QJM. 2015 Jan;108(1):19-25
pubmed: 24989780
Microbes Infect. 2004 Mar;6(3):272-8
pubmed: 15026014
J Clin Microbiol. 2009 Apr;47(4):994-1001
pubmed: 19193842
Int J Tuberc Lung Dis. 2000 Jun;4(6):584-7
pubmed: 10864192
J Clin Microbiol. 2007 Jan;45(1):237-40
pubmed: 17065260
J Clin Microbiol. 1997 Apr;35(4):907-14
pubmed: 9157152
BMC Res Notes. 2012 Jun 07;5:270
pubmed: 22676404
Lancet Infect Dis. 2007 May;7(5):328-37
pubmed: 17448936
BMC Microbiol. 2010 Jul 21;10:195
pubmed: 20663126
PLoS One. 2016 May 05;11(5):e0154571
pubmed: 27149626
Eur Respir J. 2018 Oct 18;52(4):
pubmed: 30115614
Tuberculosis (Edinb). 2015 Mar;95(2):170-8
pubmed: 25522841
BMC Microbiol. 2007 May 31;7:51
pubmed: 17540031
J Clin Microbiol. 2001 Mar;39(3):1042-7
pubmed: 11230425
Transbound Emerg Dis. 2013 Nov;60 Suppl 1:28-36
pubmed: 24171846
BMC Infect Dis. 2010 Jun 17;10:177
pubmed: 20565802
J Clin Microbiol. 1991 Nov;29(11):2578-86
pubmed: 1685494